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Abstract
Background: Melanoma is common; 15,906 people in the UK were diagnosed with melanoma in 2015 and incidence
has increased fivefold in 30 years. Melanoma affects old and young people, with poor prognosis once metastatic. UK
guidelines recommend people treated for cutaneous melanoma receive extended outpatient, hospital follow up to
detect recurrence or new primaries. Such follow up of the growing population of melanoma survivors is burdensome for
both individuals and health services. Follow up is important since approximately 20% of patients with early-stage
melanoma experience a recurrence and 4–8% develop a new primary; the risk of either is highest in the first 5 years.
Achieving Self-directed Integrated Cancer Aftercare (ASICA) is a digital intervention to increase total-skin-self-examination
(TSSE) by people treated for melanoma, with usual follow up.
Methods: We aim to recruit 240 adults with a previous first-stage 0-2C primary cutaneous melanoma, from secondary
care in North-East Scotland and the East of England. Participants will be randomised to receive the ASICA intervention
(a tablet-based digital intervention to prompt and support TSSE) or control group (treatment as usual). Patient-reported
and clinical data will be collected at baseline, including the modified Melanoma Worry Scale (MWS), the Hospital Anxiety
and Depression Scale (HADs), the EuroQoL 5-dimension 5-level questionnaire (EQ-5D-5 L), and questions about TSSE
practice, intentions, self-efficacy and planning. Participants will be followed up by postal questionnaire at 3, 6 and 12
months following randomization, along with a 12-month review of clinical data. The primary timepoint for outcome
analyses will be12months after randomisation.
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Discussion: If the ASICA intervention improves the practice of TSSE in those affected by melanoma, this may lead to
improved psychological well-being and earlier detection of recurrent and new primary melanoma. This could impact
both patients and National Health Service (NHS) resources. This study will determine if a full-scale randomised controlled
trial can be undertaken in the UK NHS to provide the high-quality evidence needed to determine the effectiveness of the
intervention. ASICA is a pilot study evaluating the effectiveness of the practice of digitally supported TSSE in those
affected by melanoma.
Trial registration: Clinical Trials.gov, NCT03328247. Registered on 1 November 2017.
Keywords: Primary care, Melanoma, Cancer, Randomised controlled trial, Survivorship, Self-directed care, e-health, ASICA,
Background
Melanoma is common; 15,906 people in the UK were diag-
nosed with melanoma in 2015 and incidence has increased
fivefold in 30 years [1]. Melanoma disproportionately affects
younger people with poor prognosis once metastatic [2].
UK guidelines recommend people treated for cutaneous
melanoma receive extended hospital follow up to detect re-
currence or new primaries [3–5]. However, delivering mel-
anoma follow up to the growing population of melanoma
survivors is burdensome for both individuals and health
services [6]. Follow up is important, nonetheless, since
approximately 20% of patients with early-stage melanoma
experience a recurrence and 4–8% develop a new primary,
the risk of either is highest in the first 5 years [7–10]. Mel-
anoma can recur locally, regionally or with distant metasta-
ses, and new primaries can occur anywhere [11].
It is important to detect new primary and recurrent
melanoma as soon as possible. Successful treatment of
recurrent melanoma with targeted and immunological
treatments is leading to significant improvements in sur-
vival even in advanced melanoma [12]. Most recurrences
and new primaries are detected by patients between
scheduled follow-up visits [3–5]. Thus, guidelines rec-
ommend patients conduct monthly total skin self-
examination (TSSE) during follow up. An American
randomised trial showed that increasing the practice
of TSSE in the short-term results in significantly
more skin surgery (i.e. in greater detection and tack-
ling of potential melanoma) in people with increased
melanoma risk [13].
However, currently people treated for melanoma are
possibly missing opportunities for early detection of new
primary and recurrent melanoma by not practising regu-
lar TSSE or not conducting it effectively. A Scottish
study suggests that people delay raising concerns about
early recurrence until their next hospital follow-up ap-
pointment [14]. There is also evidence from the UK and
elsewhere that the practice of TSSE is suboptimal and
not practised monthly as recommended by UK guide-
lines [3–5, 15, 16]. Barriers to initiating and maintaining
TSSE include lack of initial training, declining motiv-
ation and insufficient time [17]. All of these barriers are
tackled by the Achieving Self-directed Integrated Cancer
Aftercare (ASICA) intervention.
The ASICA digital intervention supports high-quality
TSSE by people with cutaneous melanoma, and appropri-
ate clinical responses when they raise a concern. It is
rigorously developed, digitally supported and theoretically
based, using specified behaviour-change techniques to
prompt users to perform regular TSSE. As reported in
more detail elsewhere [18], the intervention was designed
to incorporate specific “behaviour change techniques” or
BCTs (i.e. the active ingredients that make up an interven-
tion and are required to change behaviour). The BCTs
included aimed to develop users’ knowledge and skills
about TSSE (e.g. demonstrating the behaviour, rehearsing/
practising); enhance/maintain motivation to perform
TSSE (e.g. providing information on health consequences
of the behaviour, using a credible source for the informa-
tion); enhance confidence to conduct TSSE successfully
(e.g. mastering the skills necessary) and enable self-
regulation of action over time (e.g. providing prompts and
cues to act, planning when, where, and how to perform
TSSE). ASICA may enable earlier treatment and improved
outcomes for patients and the National Health Service
(NHS) by enabling prompt recognition and treatment of
recurrent and new primary melanomas. The ASICA
intervention was developed within the Medical Re-
search Council (MRC) complex intervention framework
[19] and includes BCTs selected to address constructs
of the underpinning theories (information-motivation-
behaviour (IMB)) model plus control theory and imple-
mentation intentions [20–25]. Development was
guided by an expert multi-disciplinary group through
several stages [18]. A systematic literature review
was conducted, followed by interviews with potential
recipients and a facilitated co-design event where all
key stakeholders participated in the development of
a prototype by acting out a full simulation: a tablet-
based digital intervention to prompt and support
TSSE, comprising instructional videos and electronic
reporting (including photographs) to a clinical nurse
specialist in dermatology with subsequent clinical tri-
age [26].
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The prototype was further developed in a preliminary 8-
month feasibility study to establish its acceptability [18].
Nineteen people treated for melanoma stages 0-2C and
who were receiving structured hospital-based follow-up
were recruited from six general practices in North-east
Scotland [18]. Users were prompted by email each month
to undertake TSSE and provide electronic feedback of
their findings to the clinical nurse specialist. Qualitative
interviews were conducted with the participants after 8
months. Most participants were strongly positive and ad-
hered well to the intervention (n = 15/19), and seven par-
ticipants reported symptoms. Two underwent surgery as a
result of participating; one with recurrent melanoma, the
second with a benign compound naevus. Intention and
confidence to conduct monthly TSSE increased. Issues to
improve usability were identified and implemented. We
concluded that ASICA is acceptable, safe and effective
and offers potential to improve psychological well-being
and enable earlier diagnosis of new primary and recurrent
melanoma [18]. However, the non-randomised pre-pilot-
study gave limited information on recruitment, acceptabil-
ity, compliance and retention at one site. Also, we col-
lected data on anxiety and depression, but not melanoma
worry, and there was wide variability in the scores at base-
line and variability in both the magnitude and direction of
effect at follow-up, raising the possibility of a bi-
directional effect on psychological outcomes that requires
further exploration. This study aims to demonstrate that
ASICA has the potential to benefit people with melanoma
and is feasible to deliver in the NHS.
Aims and objectives
The aim of the study is to compare a self-directed digital
intervention (intervention group) with treatment as
usual (control group) in patients treated for a first-stage
0-2C primary cutaneous melanoma within the preceding
60months.
The hypothesis to be tested is that among patients
with melanoma, the ASICA intervention will increase
the practice of TSSE in those who use it, compared to
controls, without affecting psychological well-being, and
will lead to earlier detection of recurrent and new pri-
mary melanoma.
The specific study objectives are to:
1. Recruit 240 adult patients with a previous first-
stage 0-2C primary cutaneous melanoma.
2. Randomise participants to the ASICA intervention
or the control group.
3. Collect baseline patient-reported and clinical data.
The baseline participant questionnaire will include
the modified Melanoma Worry Scale (MWS) the
Hospital Anxiety and Depression Scale (HADs), the
EuroQoL 5-dimension 5-level questionnaire (EQ-5D-
5 L), and questions about TSSE practice, intentions,
self-efficacy and planning.
4. Follow up participants by postal questionnaire at 3,
6 and 12 months after randomisation. Shortened
questionnaires (HADS, EuroQoL EQ-5D-5 L, and
MWS) will be completed at 3 and 6 months and a
full questionnaire, as per baseline, at 12 months.
5. Compare the primary and secondary outcomes
between the two arms.
6. Collect data from the intervention group via tablet
monitoring, for process evaluation to investigate the
frequency and patterning of total skin examination
and investigate predictors of sustained skin
examination over time.
Methods
Study design
This is a two-arm, open multi-centre randomised con-
trolled trial (RCT) comparing ASICA, a digital interven-
tion to increase TSSE by people treated for melanoma,
with usual follow up. The trial flow diagram is presented
in Fig. 1. This protocol follows Standard Protocol Items:
Recommendation for Interventional Trials (SPIRIT)
guidelines [27]. Participants will be in the trial for 12
months. The primary outcome will be determined up to
12months after randomisation.
Study participants
Inclusion criteria
We will include adults (age 18 years and over) who have
been treated within the preceding 60 months for a previ-
ous stage 0-2C primary cutaneous melanoma and can
give informed consent.
Exclusion criteria
Exclusion criteria are stage 3 and 4 melanoma; previous
local recurrence of melanoma within the last 60 months;
inability to consent and/or complete questionnaires (e.g.
due to cognitive or language issues) and blindness or
visual impairment.
Recruitment
A clinical nurse specialist in dermatology will work with
lead clinicians at the two recruiting sites, Aberdeen Royal
Infirmary and Addenbrooke’s Hospital, Cambridge. Poten-
tial participants will be identified from appropriate sources
including, but not limited to, Multidisciplinary Team
(MDT) meeting lists, locally held pathology registers and
melanoma follow-up clinic registers. Following identifica-
tion of potential participants, an invitation letter, patient
information leaflet (PIL) detailing the trial, consent form,
baseline questionnaire and pre-paid return envelope will
be sent out directly from the treating hospital. Local con-
tact details will be provided. Potential recruits will be
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offered the opportunity to meet face to face or have a tele-
phone conversation with a member of the investigative
team to discuss their potential participation. Local proce-
dures at the participating hospitals are different and the
timing and mode of approaching patients and the consent
process may vary in order to accommodate both the spe-
cific circumstances at each site and the needs of the
patients.
Informed consent
Potential participants will have the opportunity to dis-
cuss all aspects of the proposed research with the local
clinical team, family and friends and, if appropriate, with
their General Practitioner (GP). Patients who decide to
participate will send their completed documents (con-
sent form and baseline questionnaire) in the pre-paid
envelope provided to the local clinical team. Participants
Fig. 1 Flow diagram of study design and schedule. SAE, serious adverse event; ASICA, Achieving Self-directed Integrated Cancer Aftercare; HADS,
Hospital Anxiety and Depression Scale; EQ-5D, Euroqol 5-dimensions questionnaire; NHS, National Health Service
Murchie et al. Trials          (2019) 20:318 Page 4 of 11
will be asked to consent to being randomised to receive
ASICA or to the control group; to permit the research
team to review their secondary-care medical notes at
baseline and outcome; to receive the study question-
naires and for future contact to enable longer-term fol-
low up of both groups.
Randomisation and allocation
Participants will be randomised using a minimisation al-
gorithm based on gender and centre, to minimise imbal-
ance between the intervention and control groups [28].
All participants who enter the trial will be logged with
the central study office in Aberdeen and given a unique
study number. Participants will be randomised 1:1
control-to-intervention, using the validated remote auto-
mated computer randomisation application at the study
administrative centre in the Centre for Healthcare Ran-
domised Trials (CHaRT) in the Health Services Research
Unit (HSRU), University of Aberdeen. This randomisa-
tion application will be available as an Internet-based
service. The Principal Investigator (PI), or individual
with delegated authority at the site, will access the Web-
based system to randomise participants. Participants will
be informed of their allocated treatment group after
randomisation.
The intervention that will be evaluated
The intervention will be evaluated as follows:
1. Preparation and training: the intervention group
will attend a local medical photography suite to
have digital skin images taken. The ASICA
intervention app and individual skin-maps will be
incorporated within a password-protected individ-
ual tablet computer to ensure confidentiality. The
app is Android-configured and designed to run on a
Samsung Galaxy tablet. The ASICA app comprises
(1) an instructional video demonstrating how to
conduct a sequential TSSE; (2) a digital skin map of
the patient’s own skin; (3) a digital camera and in-
structions about how to take photographs of skin
lesions; (4) a structured electronic TSSE report
form, which can be sent to a clinical nurse skin can-
cer specialist (CNS), which can include photographs
of skin lesions that the patient is concerned about.
All reports are managed within a secure encrypted
server. Participants randomised to the ASICA inter-
vention will be invited to receive their tablet com-
puter at a 60-min group training session held at the
local recruiting centre. At these sessions interven-
tion group participants will be instructed how to
use the tablet computer and ASICA app to guide
themselves through TSSE and send the findings
electronically to the study server. Participants will
have the opportunity to familiarise themselves with
their tablet for a short time before their first skin
TSSE. All aspects of using the tablet, from ensuring
the internet is connected, detailed step by step in-
struction, contact details, screen shots of the app to
hints and tips on taking photographs with the tablet
are contained in a booklet that will be issued to
each participant.
2. Prompting to use ASICA: the intervention group
will be supported by a clinical nurse specialist in
dermatology based in Aberdeen and each month
they will be prompted (using the participant’s
favoured method of contact (phone, email, text or
mail) to conduct a TSSE.
3. Performing and reporting TSSE using ASICA:
participants will be asked to follow the TSSE
procedure outlined in the integral animated ASICA
demonstration and respond using the electronic
report form. Where the participant finds a skin
lesion that raises concern (either new or associated
with their primary site) they will take photographs
of the lesion using the camera on their tablet
computer. Such photographs will be uploaded and
attached to the digital report sent to the clinical
nurse specialist.
4. Response by the clinical nurse specialist: the digital
reports will be sent to the clinical nurse specialist
who will check and log them. The clinical nurse
specialist will log all data on TSSE activity (check
TSSE conducted, body areas (1–8) checked,
concerns noted) and data will be exported into the
database for process analysis.
5. Action where the report causes concern: where a
patient has registered a concern within their digital
report about something they have found during
TSSE, the clinical nurse specialist will observe this
from the report and contact the patient within 72
working hours for further discussion. They will
discuss concerns by telephone in the first instance.
Clinical images will be reviewed and further images
sent if required. Our pilot study suggests many
concerns will be successfully resolved at this early
stage.
6. Further clinical action: where discussion and review
of clinical images has not fully resolved the
concerns of the patient and/or clinical nurse
specialist, the clinical nurse specialist will discuss
the case and review any clinical images with the
site’s lead dermatologist, and an urgent clinic
appointment will be arranged.
All participants (intervention and control) will con-
tinue to attend their usual structured melanoma follow
up as determined by local guidelines throughout the
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trial. Usual structured melanoma follow up consists of
regular (3-monthly or 6-monthly) review appointments
with a specialist skin physician or nurse conducted at
the secondary care hospital outpatient department. The
schedule of appointments is determined by the clinical
features of the participant’s primary melanoma.
Follow-up procedures
Intervention and control group participants will receive
postal questionnaires at 3, 6 and 12months after ran-
domisation. Reminders will be sent to non-responders
after 3 weeks. The medical notes of all participants will
be reviewed at 12 months and any relevant pathology
data will be collected.
Subsequent arrangements
The local Research Nurse and/or PI will:
1. File a copy of the consent form in the hospital
notes along with information about the study.
2. Enter study data on the participant into the bespoke
study database hosted by the CHaRT in the Health
Services Research Unit, University of Aberdeen.
3. Maintain study documentation at main research
office. A copy of the signed consent form will be
returned to the Trial Office in Aberdeen.
4. Provide any relevant follow-up clinical data.
Participants will be asked for their preferred mode of
contact to be prompted to conduct a monthly TSSE, by
phone, post or email. In the case of non-return of ques-
tionnaires, attempts will be made by site staff or staff at
the Trial Office to trace the participant directly using
these means or indirectly by contacting the GP.
Change of status/withdrawal procedures
Participants will remain in the trial unless they choose
to withdraw consent or if they are unable to continue
for a clinical reason. All changes in status with the ex-
ception of complete withdrawal of consent will mean the
participant is still followed up for all trial outcomes
wherever possible. All data collected up to the point of
complete withdrawal will be retained (with permission)
and used in the analysis. The study team will attempt to
collect the tablet computer issued to the withdrawing
participant.
Outcome measures
Primary outcome
The co-primary outcome measures are the impact of
ASICA on worry about melanoma (the Melanoma Worry
Scale (MWS)), anxiety and depression (HADS) and quality
of life (EQ-5D-5 L) 12months after randomisation.
Secondary outcomes
1. Adherence to TSSE recommendations in the year
following the introduction of ASICA.
2. Detection of second primary and recurrent
melanoma.
3. Intention and self-efficacy and clearer plans to per-
form TSSE in the next 12 months. Intention, self-
efficacy and plans will be measured using the base-
line and outcome questionnaire measures.
4. Pattern of NHS resource use.
Data collection and processing
Follow up will continue for 12months from the date of
randomisation. Outcomes will be assessed by participant-
completed questionnaires at baseline and 3, 6 and 12
months after randomisation. The research nurse and/or
clinician will complete the case report form (CRF) at base-
line and at 12months after randomisation. The compo-
nents and timing of follow-up measures are shown in
Fig. 2 (SPIRIT Figure [27])
Baseline
A participant visit will not be required to collect baseline
data as these will be obtained from participants’ hospital
medical records and by postal questionnaire. Participants’
details (age, gender, ethnicity, habitation status, occupa-
tion, GP practice, date of melanoma diagnosis, clinical
details about melanoma, important comorbidities) will be
recorded in the electronic CRF. NHS resource use with
respect to skin services will be collected for the 2 years
preceding randomisation including number of melanoma
follow-up appointments and grade of clinician seen; the
number, type and duration of skin-related hospital admis-
sions and the number of additional skin-related hospital
outpatient attendances and the grade of physician seen.
Participants will complete a questionnaire collecting data
on quality of life (EQ-5D-5 L [29]), anxiety and depression
(HADS [30]), worry about melanoma (MWS) [31]), self-
report of health service use, self-report of TSSE practice
(frequency and coverage) and ratings of intention, self-
efficacy and planning for future TSSE [32].
Follow up
Participants will be asked to complete a questionnaire,
similar to the baseline questionnaire, to assess outcome
measures at 12 months, with a shortened questionnaire
at 3 and 6months after randomisation. These question-
naires will be administered by post or email as preferred
by the participant. The research nurse will also re-review
participants’ medical records at outcome to collect data
on skin-related NHS resource use during the study year,
including details of any new skin-related diagnoses and
details of melanoma follow-up appointments and other
Murchie et al. Trials          (2019) 20:318 Page 6 of 11
skin-related hospital attendances and admissions. The
CRF will enable the clinical nurse specialist to collect
relevant baseline and outcome data from secondary care
case-notes (including pathology data).
Additional data from the intervention group
Adherence to TSSE will be measured using reports of
TSSE from the intervention group, which will provide
information on the frequency and pattern over time of
TSSE, maintenance throughout the 12months, the time
taken and the areas of the body covered. These data will
be analysed to assess usage and predictors of usage of
ASICA that might be useful in designing improvements
to the procedures.
The research nurses will enter locally collected data
at the trial centres. Serious adverse events and ad-
verse events will be notified immediately to the PI
and recorded by the Trial Office in Aberdeen. Staff in
the Trial Office will work closely with the local Re-
search Nurses to ensure the data are as complete and
accurate as possible. Study questionnaires will be sent
to participants from the Trial Office in Aberdeen and
participants will return the completed questionnaires
to the Trial Office. Extensive range and consistency
STUDY PERIOD
Recruitmen
t
Intervention 
(Monthly 
prompt for 
skin check)
Post-allocation Close-out
TIMEPOINT** -t1 0-12 mths 3mth 6mth 12mth 12mth
ENROLMENT:
Eligibility screen Xa
Informed 
consent X
a
Randomisation Xa
Allocation Xa
INTERVENTIONS
:
ASICA 
Intervention X
Control group 
(usual care)
ASSESSMENTS:
Demographics
Xa
Medical history
Xa Xa,b
Skin-related 
health service 
use
Xa,b Xb Xb Xa,b
quality of life 
(EQ-5D)
Xb Xb Xb Xb
Anxiety and 
depression 
(HADS)
Xb Xb Xb Xb
Melanoma worry 
scale (MWS)
Xb Xb Xb Xb,c
Self-report of 
TSSE practice
Xb Xb Xb Xb
Self-report TSSE 
intention
Xb Xb Xb Xb
Self-report TSSE 
self-efficacy
Xb Xb Xb Xb
Self-report TSSE 
future plans
Xb Xb Xb Xb
Fig. 2 Schedule for assessments/data collection (Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) [27]. mth, months;
ASICA, Achieving Self-directed Integrated Cancer Aftercare; EQ-5D, Euroqol 5-dimensions questionnaire; HADS, Hospital Anxiety and Depression
Scale; MWS, Melanoma Worry Scale; TSSE, total skin self-examination
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checks will be used to further ensure the quality of
the data.
Sample size
A formal power calculation is not needed as this is a
pilot trial. However, we have made a pragmatic choice to
conduct a relatively large (n = 240) pilot study for several
reasons. The non-randomised pilot [18] of 19 patients
gave limited information on recruitment, acceptability,
compliance and retention at one site. We collected
HADS (but not MWS) data at baseline and at 6-month
follow up. There was wide variation in the scores at
baseline and variability in both magnitude and direction
of effect at follow up. The feasibility study has therefore
raised the possibility of a bi-directional effect on psycho-
logical outcomes, with a possible gender interaction,
which now needs further exploration in a sample of suf-
ficient size to have representation across the spectra of
anxiety and cancer worry scales in both sexes and we be-
lieve this will be captured amongst 240 individuals. We
need to ensure that ASICA does not adversely affect
psychological outcomes and that there will be good
adherence to ASICA in most participants, thereby con-
firming that ASICA could work within the NHS, before
proceeding to a definitive trial powered to evaluate
harder clinical outcomes (e.g. rates of recurrence and
new melanoma, both quantified in the current study).
Pragmatically therefore, we believe a sample size of 240
will provide a sufficiently diverse group of participants
to provide this information. Although our trial is not
powered to detect significant differences in clinical out-
comes between groups it will provide valuable informa-
tion on trial processes and on psychological and clinical
outcomes to inform a definitive trial.
Statistical analysis
The Medical Statistics Team at the University of Aber-
deen will be responsible for the statistical aspects of the
trial. Data from patient case-notes, on the use of ASICA
and from participant questionnaires will be entered into
a dedicated secure website. In accordance with Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines, primary analysis will be intention to treat, with a
per-protocol sensitivity analysis. No interim analysis is
planned. Baseline comparability between the interven-
tion and control group in demographic characteristics,
MWS, HADS and EuroQuol EQ-5D-5 L scores, self-
reported TSSE practice, intention, self-efficacy and plans
and clinical data will be evaluated by examining sum-
mary statistics (mean (SD) or median (IQR) for continu-
ous variables, dependent on distribution and number
(percentage) for categorical variables). Confidence inter-
vals of between-group differences in the primary and
secondary outcomes will be estimated using a repeated
measures mixed model, before and after adjustment for
potential confounders (including centre, age, gender,
deprivation, baseline performance). The confidence in-
tervals generated from the model will subsequently in-
form a power calculation for a definitive trial. The
primary timepoint for outcome analyses will be 12
months after randomisation. The 1-year rate of detection
of new primary melanomas, melanomas in-situ, dysplas-
tic melanocytic lesions and recurrent melanomas will be
tabulated by randomisation group. Service use and cost
data will be summarised by group and compared using a
mixed model approach before and after adjustment for
pre-specified confounders. The relationship between
ASICA usage data, including TSSE trajectories, and out-
comes within and between intervention group partici-
pants will be examined by multilevel modelling;
predictors of usage (including demographic, question-
naire and early TSSE) will be examined in between-
participant analyses. Effect sizes of the primary
outcomes will be calculated and practical issues affecting
the conduct of a definitive RCT summarised. A compre-
hensive statistical analysis plan will be agreed by the
Trial Steering Committee (TSC) prior to any analysis.
Economic evaluation
A health economist will advise the study statistician
on assigning the appropriate unit costs to items of
service use for a preliminary assessment of costs. The
totality of the data will enable costs, practical issues
and effect sizes to be identified for a future definitive
RCT of the ASICA intervention. Data collection in
the trial will focus on estimating the costs of the
intervention and the use of primary or secondary
NHS care by study participants. Participant costs will
comprise self-purchased healthcare (e.g. prescription
and over-the-counter medication related to the skin).
Information will be collected using the participant-
completed baseline, 3, 6 and 12-month questionnaires.
Participants will be asked for information about use
of private healthcare. Health service costs incurred as
a consequence of the intervention will be recorded.
Information on non-protocol visits made to any pri-
mary or secondary care provider will be obtained
from the questionnaires at baseline and 3, 6 and 12
months and from the secondary care medical record
review.
Process evaluation
In parallel with the quantitative analysis of study data we
will conduct a process evaluation of the ASICA inter-
vention and of how it has functioned during the trial.
The process evaluation will follow the principles of the
Medical Research Council (MRC) process evaluation
guidance and will primarily investigate the practical
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issues around the implementation of the ASICA inter-
vention [33]. It will also consider how the intervention
has produced any observed and statistically significant
changes between the intervention and control groups
with respect to the primary and secondary outcomes.
Finally, the process evaluation will consider the impact
of context on how the intervention has worked at the
two study sites.
Patient and public involvement
A facilitated co-design event attended by multiple stake-
holders and involving five healthy volunteers was con-
ducted in 2015; this helped us to develop the research
questions and outcomes for the trial. This was combined
with a short feasibility study in which 19 people treated
for melanoma used the prototype for 8 months [18].
Patients’ priorities, experience and preferences expressed
during these exercises helped to form the research ques-
tions and outcome measures for the study. This exercise
also helped determine the burden of the intervention for
trial participants, with prototype users confirming the
feasibility of the intervention. During this trial two pa-
tient participants will form part of the Trial Steering
Committee; these participants have been consulted
throughout the design and recruitment and will con-
tinue to meet, receive and discuss reports for the dur-
ation of the study. A digest of trial results will be offered
to all study participants on completion of the study.
Research governance, data protection and
sponsorship
The trial will be run under the auspices of CHaRT based
at HSRU, University of Aberdeen. This will support
compliance with research governance, and provide cen-
tralised trial administration, database support and eco-
nomic and statistical analyses. CHaRT is a registered
Clinical Trials Unit with particular expertise in running
multicentre RCTs of complex and surgical interventions.
The Chief Investigator (CI) will, with the support of
CHaRT, ensure that adequate systems are in place for
monitoring the quality of the trial and appropriate expe-
dited and routine reports, to a level appropriate to the
risk assessment of the trial.
Data collected during the course of the research will
be kept strictly confidential and accessed only by mem-
bers of the trial team. Participants’ details will be stored
on a secure database under the data protection guide-
lines and regular checks and monitoring are in place to
ensure compliance. Data will be archived to a secure
data storage facility. The senior information technology
(IT) manager (in collaboration with the CI) will manage
access rights to the data set. Participants will be allo-
cated an individual specific trial number and their details
will be anonymised on the secure database. We
anticipate that anonymised trial data may be shared with
other researchers to enable international prospective
meta-analyses.
Dissemination
The findings from the ASICA trial will be disseminated
via publication in appropriate scientific journals, presen-
tation at peer-reviewed scientific conferences, and to
stakeholders including patients, clinicians, the public
and policymakers at appropriate local, national and
international meetings.
Data handling, record keeping and archiving
Essential data will be retained for a period of at least 5
years following close of trial. Electronic data will be
archived by CHaRT. The archiving procedures for hard-
copy documentation held at local sites will be performed
as documented in the Sponsor site agreement. Data will
be archived in the Health Sciences Building archive as
per Sponsor’s standard operating procures.
Satellite studies
It is recognised that the value of the trial may be en-
hanced by smaller ancillary studies of specific aspects of
the data, for example differential recruitment from rural
and urban areas and predictors of different levels of
TSSE adherence. Plans for these will be discussed in ad-
vance with the Project Management Group. Sponsor
and Research Ethics Committee (REC) approval will be
sought for any new proposal, if appropriate.
Discussion
This study will determine the effectiveness of the ASICA
intervention in evaluating the effectiveness of total skin
self-examination practice in those affected by melanoma.
The study is timely given the growing interest and re-
search activity around digital healthcare interventions in
modern health services. Good-quality evidence is needed
to inform policy and best practice in the field. This re-
search project will implement and evaluate a rigorously
developed and theoretically based digital intervention
with real potential to improve patient outcome and the
efficiency of services. A relatively large randomised con-
trolled pilot trial is proposed. This will afford the oppor-
tunity to establish overall feasibility and trial procedures;
however, the sample will be big enough to enable insight
into practical issues from the perspective of the different
population groups that would take part in a definitive
trial and amongst whom the intervention would ultim-
ately be implemented. A further important aspect of
digital interventions is the potential impact they could
have on wider resource use - in this case there is the
possibility of a large increase in the use of skin-related
NHS contacts. For this reason, data are being collected
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to determine any major impact on NHS resources at the
earliest possible stage in the evaluation of this interven-
tion. Further, the trial is designed to capture how well
potential recipients of a digital intervention can actually
use it and to exclude any major psychological impacts in
the short-to-medium term. The addition of a structured
process evaluation will lend insight into the practical is-
sues of instituting and delivering this intervention. This
is especially important given the two proposed study
sites. This comes closer to modelling the challenges of
implementing digital healthcare intervention than many
digital pilot trials and is likely to provide information of
value to others conducting research in the field, which
goes beyond the specifics of this trial.
Trial status
Currently recruiting. Participant recruitment began in
January 2018 and is expected to finish recruiting in Feb/
March 2019. The first participant was randomised on 24
January 2018. Currently approved protocol: Version 2, 1
December 2018.
Additional file
Additional file 1: Completed SPIRIT checklist for the ASICA trial
protocol. (DOCX 24 kb)
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